

Annual Meeting 2023 – Oral Presentation Schedule

Oral Session 1 – Monday 26 June, 14:40 – 15:40

Title: OS01 - Innovative Insights in Disease Management

Room	OP	Title	Presenter
Riverbank 8	OP01	Causal Association between Type 2 Diabetes Mellitus and Risk of Cancer	Fabiola Lemus
	OP52	Treating Osteoporosis in Postmenopausal Women with Denosumab (Prolia®): A Systematic Review and Network Meta-Analysis	Magdalena Ruth Moshi
	OP04	The Efficacy of Segmentectomy and Lobectomy for Non-Small Cell Lung Cancer 1-2 cm: A Systematic Review and Meta-Analysis	Kai Zhao
	OP159	Quality of Evidence and Clinical Benefit of Cancer Medicines Assessed for Funding in Australia	Agnes Vitry

Title: OS02 - Patient Involvement in HTA: Tools & Challenges

Room	OP	Title	Presenter
Plenary Room	OP06	Development of a Tool to Support the Collection of Policy-Relevant, Stakeholder-Informed Clinical Evidence for Innovative Digital Health Technologies	Amy Von Huben
	OP07	Eleven Years of CONITEC: Advances and Challenges of Patient and Public Involvement in Brazilian Health Technology Assessment Process	Clarice Moreira Portugal
	OP08	International Benchmark of Health Technology Assessment Training Tools and Materials for Patients and Consumers	Eunice Low
	OP09	Developing a Patient and Consumer Training Tool Explaining Health Technology Assessment and Patient/Consumer Participation: The French Experience	Eunice Low

Title: OS03 – Global Perspectives on Cost-Effective Cancer Therapies

Room	OP	Title	Presenter
Riverbank 6	OP11	Cost-Effectiveness of Atezolizumab plus Chemotherapy as First-Line Treatment for Metastatic Non-Squamous Non-Small Cell Lung Cancer.	Liu Liu
	OP12	Cost-Effectiveness Comparison of PD-(L)1 Inhibitors in First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in China	Yi Yang
	OP13	Cost-Effectiveness Analysis of Sintilimab plus Chemotherapy for the First-Line Treatment of Non-Squamous Non-Small-Cell Lung Cancer: Societal Perspective	Fuming Li

	OP14	Cost-Utility Analysis of Regorafenib for Patients with Hepatocellular Carcinoma who Progressed on Sorafenib Treatment	Ambrish Singh
--	------	---	---------------

Title: OS04 – Building Global Capacity for HTA

Room	OP	Title	Presenter
E1	OP10	Standardised Multi-Lingual Reporting of Health Technology Assessment and Stakeholder Involvement	Jack Nunn
	OP18	Laying the Foundation for Sustainable Health Technology Assessment Training Program in Ukraine	Rabia Sucu
	OP19	Exploring the Environment/Capacity of South African Citizen Actors to Contribute to HTA Processes, Policy Development and Institutionalisation	Lauren Pretorius

Title: OS05 – Patient Values, Gender Medicine in HTA: Insights from Cancer, Mental Health & Surveys

Room	OP	Title	Presenter
Riverbank 3	OP21	Patient Values Project (PVP): Patient preferences for Cancer Treatments to Inform a Framework Incorporating Patient Values into HTA	Deborah A Marshall
	OP22	Benchmarking of Population-Based Childhood Cancer Survival by Toronto Stage: Know the Differences to Propose Effective Interventions	Rosalia Ragusa
	OP45	HTA and Gender Medicine: Time to Take Action!	Rosalia Ragusa
	OP24	Depressed and Depression-Prone Groups' Preference with regard to Antidepressants in China: A Best-Worst Scaling Survey	Shimeng Liu

Title: OS07 – Healthcare Models: Economic Evaluation

Room	OP	Title	Presenter
Riverbank 4	OP31	Societal Opportunity Costs: Incorporating Impacts that Fall Outside the Healthcare Sector	Laura Edney
	OP32	Health Service Delivery Models for Patients with Severe Mental Illness: A Systematic Literature Review of Economic Evaluations	Anne Kleijburg
	OP33	Child and Adolescent Mental Health Care Models: A Scoping Review	Ingrid Zechmeister-Koss
	OP34	Application of a Case-Mix Analysis in COVID-19 Management at a University Hospital in Malaysia	Amirah Azzeri

Title: OS08 – Empowering Healthcare Decisions: Equity, Multimorbidity, RWE & AI

Room	OP	Title	Presenter
Gilber	OP37	Modelling the Effect of Multi-indication Treatment in Multimorbid Patients Using Population-Scale Linked Electronic Health Records for Healthcare Policy	Rhiannon Owen

	OP39	Real-World Evidence of Pos-Incorporation Use of Monoclonal Antibodies for Psoriasis in the Brazilian Public Health System	Stéfani Sousa Borges
	OP115	Scoping Meta-Review on Methods used to Assess Artificial Intelligence Based Medical Devices for Congestive Heart Failure	Rossella Di Bidino

Title: OS09 – Bridging HTA Regulations & Real-World Practice: Lessons & Future Directions

Room	OP	Title	Presenter
E3	OP41	Gap Analysis of EU Regulations Related to Real World Evidence Generation	Entela Xoxi
	OP43	Translating Cell and Gene Therapy HTA into Practice - Building the Plane as we Fly it	Paul Fennesy
	OP44	Exploring the Disconnect in Relevant Outcomes for HTA-Related Economic Evaluation Relative to Care Commissioning: Implications for Resource-Allocation	Rachael Hunter
	OP29	Impact of New Drug Indications After Initial Registration by ANVISA - Brazil	Marcus Borin

Title: OS10 – Addressing Uncertainty in HTA & Pricing

Room	OP	Title	Presenter
Riverbank 7	OP46	The Decision Uncertainty Toolkit: Risk Measures and Visual Outputs to Support Health Technology Decision-making During Public Health Crises	Erin Kirwin
	OP47	The Risk-Based Price: Incorporating Uncertainty and Risk Attitudes in Health Technology Pricing	Erin Kirwin
	OP48	Is It Time for (Disease-Specific) Reference Models?	Hossein Afzali
	OP27	Impact of Generic Entry of Pharmaceuticals on Drug Prices in Australia	Hansoo Kim

Title: OS11 – Innovations in HTA Research & Practice

Room	OP	Title	Presenter
Riverbank 5	OP171	Canadian Disease Registry Inventory: Environmental Scan of the Literature	Amanda Hodgson
	OP172	International Collaboration for Translating the Peer Review of Electronic Search Strategies (PRESS) Checklist: A Harmonized Approach	Amanda Hodgson
	OP23	Early Detection Tools for Emotional Distress in Adult Cancer Patients in Spain: A Health Technology Assessment Report	María José Faraldo-Vallés
	OP68	Exploring the Diversity of Interventions in Healthcare and Social Care: A Road to Priority Setting and Sustainability	Sylvie Bouchard

Oral Session 2 – Tuesday 27 June, 13:45 – 14:45

Title: OS12 – RWE & Economic Evaluation in Chronic Diseases

Room	OP	Title	Presenter
Riverbank 6	OP51	Use of Real-World Data in Cost-effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis	Janharpreet Singh
	OP03	Comparative Safety and Efficacy of PD-(L)1 Inhibitors for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis	Yi Yang
	OP53	Return on Investment of Fracture Liaison Services: A Systematic Review	Lizheng Xu
	OP54	Experiences on Out-of-Hospital Drug Treatment for Systemic Lupus Erythematosus: A Thematic Synthesis	Clarice Portugal

Title: OS13 – Empowering Patients in HTA: Opportunities and Challenges

Room	OP	Title	Presenter
Plenary Room	OP55	Did It Matter? Developing a Common Framework for Characterizing Impact of Patient Involvement in Health Technology Assessment	Anke-Peggy Holtorf
	OP56	Conversations for Change’ – Identifying Meaningful Ways to Improve Consumer Participation in Health Technology Assessment Processes	Sally Wortley
	OP58	Challenges In Maintaining Up to Date Health Technology Assessments in Rare Diseases: Lessons from Fabry Disease In Australia	Michel Tchan
	OP57	Consumer Engagement in Health Technology Assessment: An Australian Journey to Date	Jo Watson

Title: OS14 – Innovative HTA: Disinvestment, Digital Health, Risk Adjustment

Room	OP	Title	Presenter
E3	OP59	Do Digital Health Terms Provide Sufficient Information to Allow for Health Technology Assessment?	Rossella Di Bidino
	OP60	Community Funding Prioritisation of Treatments for Rare and Ultra-Rare Medical Conditions	Samson Kong
	OP61	Value of Disinvestment: The Journey from Possibility to Reality	Izzuna Ghazali
	OP62	Development of the Oral-Health Risk Adjustment Model to Predict the Outpatient Dental Expenditure in Children with Autism	Mei-chi Lai

Title: OS15 – HTA Innovations: Machine Learning to Real-World Evidence

Room	OP	Title	Presenter
Riverbank 8	OP63	Incorporating Machine Learning Methods in Health-Economic Evaluations: A Case Study on Depression Prevention	Joran Lokkerbo
	OP106	Standing on the Shoulders of Giants: Adapting Published Health Technology Assessments on Medical Technologies to Singapore’s Context	Lydia Ooi

	OP66	Adoption of the Who Algorithm for Essential Medicines in the Philippine National Formulary Listing Process	Sheena Jasley Samonte
	OP74	Analysis of Literature and Research Foci in Overdiagnosis Based on CiteSpace	Juntao Yan

Title: OS16 – Advancing Healthcare: Repurposing, Adoption & Economic Analysis

Room	OP	Title	Presenter
Gilbert Suite	OP67	Horizon Scanning for Repurposed Medicines	Aoife Oliver
	OP173	Estimating the Marginal Productivity of Health Technology Adoption	Charles Yan
	OP95	A Systematic Review of the Cost and Cost-effectiveness of Immunoglobulin Treatment in Patients with Haematological Malignancies	Sara Carrillo De Albornoz
	OP70	Treating Patients with Hormone-Sensitive Cancer on Endocrine Therapy with Denosumab (Prolia®): A Systematic Review and Network Meta-Analysis	Konstance Nicolopoulos

Title: OS18 – Cost-Effectiveness of Smoking Cessation & Lung Cancer Screening

Room	OP	Title	Presenter
Riverbank 4	OP75	Cost-effectiveness of Brief Advice to Quit Smoking to Prevent Postsurgical Complications in People Living with Cancer	Nikki Mccaffrey
	OP77	Distributional Cost-Effectiveness Analysis of Lung Cancer Screening for Indigenous and Non-Indigenous Populations in Australia	Jackie Roseleur
	OP78	Cost-Effectiveness of a 20-Valent Pneumococcal Conjugate Vaccine to Directly Protect Adults against Pneumococcal Disease in England	Diana Mendes
	OP71	Road to Public Funding of Cancer Co-dependent Technologies in Australia in the Last 10-Years	Yuan Gao

Title: OS19 – Economic Evaluation & Diagnostic Technologies

Room	OP	Title	Presenter
Riverbank 3	OP79	Gene Expression Profiling in the Diagnosis of Aggressive Large B Cell Lymphoma: An Early Exploratory Economic Evaluation	Janet Bouttell
	OP80	Diagnostic Molecular Sequencing of DNA (Exomes and Genomes) Is Not Perfect: Implications for HTA	Camille Schubert
	OP81	Cost-Effectiveness of Human Papillomavirus Extended Genotyping for Cervical Cancer Screening in Singapore	Brandon Chua
	OP82	Positron Emission Tomography Combined with Computed Tomography (PET/CT) using 18F-NaF	Nasrulla Shanazarov

Title: OS20 – Economic Evaluations: Diagnostic & Therapeutic Interventions

Room	OP	Title	Presenter
Riverbank 5	OP83	Diagnostic Accuracy and Cost-Effectiveness of Automated ABPI Measurement for Assessing Peripheral Arterial Disease in People with Leg Ulceration	Dwayne Boyers
	OP84	Cost-Effectiveness of Testosterone Treatment (TT) for Men with Hypogonadism	Rodolfo Hernández
	OP85	Cost-Effectiveness Of Prednisolone to Treat Bell’s Palsy in Children: An Economic Evaluation Alongside a Randomized Controlled Trial	Xiuqin Xiong
	OP86	Cost-effectiveness of High-Sensitivity Troponin Testing in the Investigation and Management of Chest Pain in the Emergency Department	Aubyn Pincombe

Title: OS21 –Patient-Centered Care in HTA

Room	OP	Title	Presenter
Riverbank 7	OP87	A Roadmap for Increasing the Usefulness and Impact of Patient Preference Studies in Health Technology Assessment (HTA)	Deborah A Marshall
	OP88	Translating Patient Reported Measure Score into Specific Outcomes from the Patient Perspective – Example Using Health Assessment Questionnaire-Disability Index	Adrian Griffin
	OP98	Improving Patient Involvement in Health Technology Assessments: Is it Enough to Train just the Patients?	Jennifer Prescott
	OP90	Multiple Myeloma: Developing a Benchmark Patient Experience Index – Australia and New Zealand	Jenni Godsell

Title: OS22 – Healthcare Operations & Management

Room	OP	Title	Presenter
E1	OP25	Increasing Harmonisation through Improving Uptake of Core Outcome Sets in Clinical Trials and Systematic Reviews	Sean Tunis
	OP176	Integrating Real-World Compliance in the Assessment of Left Atrial Appendage Closure versus Anticoagulation Therapy in Non-Valvular Atrial Fibrillation	Dominic Tilden
	OP05	HTA Role In Carving the Pathway for Better Access to Immunotherapy in Advanced NSCLC in Malaysia	Erni Zurina Romli
	OP72	Innovating to Decrease Mortality and Resource Use in Surgical Inpatient: ZERO project	Carla Fernández-Barceló

Oral Session 3 – Tuesday 27 June, 17:30 – 18:30

Title: OS23 – Economic Evaluations in Healthcare: Insights from Systematic Reviews

Room	OP	Title	Presenter
E2	OP92	The Hidden Burden of Patients and Families in Rare Diseases: A Scoping Review of Economic Evaluations	Deborah Marshall
	OP93	The Cost-Effectiveness of Antiretroviral Therapy Adherence Interventions in HIV/AIDS Patients: A Systematic Review of Decision Analytic Models	Ali Ahmed
	OP94	Economic Evidence on Haemodialysis Access Creation Procedures in Patients with End-Stage Kidney Disease: A Systematic Literature Review	George Papdopolous

Title: OS25 – Advancing HTA for Global Health: Insights and Roadmaps

Room	OP	Title	Presenter
E1	OP101	Health Technology Assessment for Sexual Reproductive Health and Rights Packages in Sub-Saharan Africa: Review of Evidence-Informed Deliberative Processes	Warren Mukelabai Simangolwa
	OP102	Towards Universal Health Coverage: Health Technology Assessment Roadmap Development in the Emirate of Abu-Dhabi Involving the Whole Ecosystem	Amna Alsaeedi
	OP103	What to Include in a Health Technology Assessment of Artificial Intelligence-Based Technologies: Results of a Delphi Expert Survey	Rossella Di Bidino
	OP104	Pilot Implementation of the HTA Topic Prioritization in the Philippines: Lessons and Moving Forward Plans	Sheena Jasley Samonte

Title: OS26 – Innovations in HTA: Processes, Perspectives and Value

Room	OP	Title	Presenter
Riverbank 8	OP107	Streamlining Health Technology Assessment Process of Medical Devices through the Development of the Philippine Essential Medical Device List	Patrick Wincy Reyes
	OP109	The Conceptualization and Value of a Disease Management Approach to HTA in Canada: Findings from a Qualitative Study	Marina Richardson
	OP100	Patient Perspectives in Value Assessment Frameworks: The Asia Pacific Perspective	Alex Best

Title: OS28 – Empowering Patient Involvement in HTA: Collaborative Approaches & Future Perspectives

Room	OP	Title	Presenter
Pleinar	OP116	Building Alignment Between Industry, Academia and Patients on HTA Methods	Colman Taylor
	OP125	How can HTA Evolve to Better Consider Benefits for Patients, their Families and Carers?	John Gillespie

	OP120	Developing a Call to Action for Patient Involvement in HTA in Southern Africa.	Lauren Pretorius
	OP96	Adapting Patient Involvement for Fast Track Appraisals	Sam Roberts

Title: OS29 – Economic Evaluation in Cancer and Renal Disease: Cost Effectiveness Perspectives

Room	OP	Title	Presenter
Riverbank 4	OP121	Cost-Utility Analysis of a Supervised Exercise Intervention for Women with Early-Stage Endometrial Cancer	Yufan Wang
	OP122	Economic Evidence to Support Expanding Use of Existing Positron-Emission Tomography Technology as Diagnostic Tool for High-Risk Cancer Patients	Michelle Tew
	OP123	Lifetime Cost-Effectiveness Analysis in Patients with Early Hepatocellular Carcinoma Receiving Two Competitive Treatments: Liver Transplantation versus Hepatic Resection.	Yih-Jyh Lin
	OP124	Cost-Effectiveness of End Stage Renal Disease Treatment Methods in Türkiye	Mustafa Kılıç

Title: OS30 – Evaluating Effectiveness and Cost-Effectiveness in Healthcare Interventions

Room	OP	Title	Presenter
E3	OP126	Clinical and Economic Evaluation of the Effectiveness of the Cerebrolysin in Neurological Patients with Post-Stroke Complications in Kazakhstan	Andrey Avdeyev
	OP127	The Cost-Effectiveness of the Anti-VEGF Treatments for Age-Related Macular Degeneration in the Italian Healthcare Setting	Michele Basile
	OP128	Uncertainties in the Cost-Effectiveness Analysis of the Onasemnogene Apeparvovec in Spinal Muscular Atrophy Type 1	Stefani Borges
	OP129	A Cost-Utility Analysis of Denosumab (Prolia®) for Treating Osteoporosis in Postmenopausal Women: A Swiss Healthcare Payer Perspective	Danielle Stringer

Title: OS31 – Advancements in HTA and Healthcare Outcomes

Room	OP	Title	Presenter
Riverbank 3	OP133	COVIDIAGNOSTIX: HTA for COVID-19 Serological Tests as Companion Diagnostics to Employ the Vaccination	Giuseppe Banfi
	OP134	Mapping the Health of the Nation Outcomes Scale to the EQ-5D using the Pharmacotherapy Monitoring and Outcome Survey	Anne Kleijburg
	OP135	Machine Learning and Cancer Registry: Evaluation of the Effectiveness of Case Coding.	Rosalia Ragusa
	OP119	Collectively Improving the Quality Use of Highly Specialised Medicines: Starting with Biologics	Jonathan Dartnell

Title: OS32 – Global HTA: Challenges and Opportunities

Room	OP	Title	Presenter
Riverbank 7	OP136	A Comparison of HTA Recommendations in Australia, Canada and England: Is There Opportunity for Further Alignment?	Tina Wang
	OP137	A Qualitative Exploration of the National Institute for Health and Care Excellence's Impact on International Health Technology Assessment	Martina Garau
	OP138	Navigating High-Cost Medicines: Promoting Consistent, Evidence-Based Use of High-Cost Medicines in a Fiscally and Equitable Responsible Manner	Naomi Burgess
	OP40	An Initiative to Identify the Long-Term Effects of COVID-19: Ministry of Health (MoH) COVID-19 Follow-Up Centers	Olgun Şener

Title: OS33 – HTA & Economic Evaluations

Room	OP	Title	Presenter
Riverbank 6	OP112	Evaluation of a Self-Administered Smart Phone-Based Application as a Wellness Measure in a Clinical Trial of Zanubrutinib	Keri Yang
	OP38	Evaluation of High-Cost Medicine for a Rare Disease: 16-Year Cohort of Imiglucerase Use for Gaucher Disease in Brazil	Marcus Borin
	OP65	Addressing System Need Through Piloting Early Value Assessment of Digital Therapies for Mental Health	Jennifer Prescott

Oral Session 4 – Wednesday 27 June, 10:35 – 11:20

Title: OS34 – Innovations in HTA: Expert Elicitation, Disease Progression Analysis & Diagnostic Pathways

Room	OP	Title	Presenter
E2	OP141	Expert Knowledge Elicitation in Health Technology Assessment: Our Experience Using the Sheffield Elicitation Framework	Danielle Stringer
	OP142	Progression Analysis vs Traditional Methods to Quantify Slowing of Disease Progression in Alzheimer’s Disease	Milana Ivkovic
	OP168	Costs and Effectiveness of Whole Exome Sequencing (WES) in Patients with Unsolved Rare Disease through the Diagnostic Pathway	Deborah A Marshall

Title: OS35 – Health Initiatives: Knowledge, Screening, and Economic Impact

Room	OP	Title	Presenter
E3	OP144	Impact of a Training Program for General Population on the Knowledge of Aortic Valve Stenosis	Carla Fernández-Barceló
	OP145	Breast Cancer Screening Rate in Females in China: After the Implementation of Two Screening Intervention Programs	Xin Wang
	OP130	Estimating Economic Burden of “Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome” in Turkiye towards Next Decade	Birol Tibet

Title: OS36 – Impact of HTA: Insights from Healthcare Systems, Hospitals, and Stakeholders

Room	OP	Title	Presenter
Plenary Room	OP147	Measuring HTA Impact on Introduction of Transcatheter Aortic Valve Replacement in A Private Healthcare System	Marcus Borin
	OP148	Influence of the Hospital-Based HTA Unit on the New Technologies Transfer at the National level in Kazakhstan	Andrey Avdeyev
	OP149	How to Improve the Impact of Health Technology Assessment: A Stakeholders’ Perspective in Spain	María José Faraldo-Vallés

Title: OS37 – Future of HTA: Policy, Challenges & Digital Innovation

Room	OP	Title	Presenter
Riverbank 8	OP150	An Inventory of Policy Levers for Influencing Appropriate Care	Ken Bond
	OP151	Health Technology Assessment in Switzerland - Current and Future Challenges	Nicolas von Dombrowski

	OP114	Health Technology Assessment of Digital Technologies: Results from Two Past Examples and Thoughts for the Future	Jamie Erskine
--	-------	--	---------------

Title: OS38 – Advancing HTA: Bridging Data Access & Proportional Approaches and Patient Outcomes

Room	OP	Title	Presenter
Riverbank 7	OP153	Access to Real-World Data for the Use in Health Technology Assessment – Still Work to be Done	Hansoo Kim
	OP154	Horses For Courses: Developing A Proportionate Approach to Health Technology Assessment in England	Jennifer Prescott
	OP143	Association of Different Venous Access Device and Health-Related Quality of Life among Patients with Breast Cancer in China	Liu Liu

Title: OS39 –Assessing Medical Interventions

Room	OP	Title	Presenter
Riverbank 3	OP156	Systematic Review and Meta-Analysis of the Perioperative Association of Gabapentinoids with Sedation and Respiratory Depression after Abdominal Surgery	Laure Taher Mansour
	OP157	Evaluating the Clinical and Economic Impact of Adopting a Closed Peripheral Intravenous Catheter System in a Japanese Hospital	Yan Ma
	OP158	Point of Care Testing in Primary Care: How to Add Value to Economic Evidence to Argue for Adoption	Rachael Hunter

Title: OS41 – Local Economic Evaluation and HTA

Room	OP	Title	Presenter
Riverbank 6	OP162	Making Local Economic Evaluation More Relevant: Using Expert Elicitation to Adjust Published Intervention Effects to Reflect Local Context	Jodi Gray
	OP163	Applying a Local Economic Evaluation Framework to Make Evaluations More Relevant for Local Decision Makers	Jodi Gray
	OP174	HTA and Economic Evaluations for a Genomic Strategy in Italy	Eugenio Di Brino

Title: OS42 – Analyzing HTA in Brazil: Decision Criteria, RWE & Medication Exclusion

Room	OP	Title	Presenter
Riverbank	OP165	Changing Decision Criteria: An Analysis of Health Technology Assessment Reports to Brazilian Health Unified System	Stefani Borges

	OP152	Use of Real-World Evidence by the Brazilian HTA Committee (CONITEC) for Monitoring of Health Technologies	Clarice Moreira Portugal
	OP167	An Analysis of Medication Exclusion Reports in the Health Technology Assessment Process for the Brazilian Unified Health System	Stefani Borges